Effects of the modified electric convulsive treatment (MECT) on cell factors of schizophrenia

Guo,Yong‑Fang; Fu,Hua‑Bin; Liu,Zhi‑Yuan; Lu,Wei; Luo,Ke‑Yong; Zhu,Hong‑Ri; Ning,Wei‑Dong; Chen,Feng; Yang,Li-Yu; Zhou,Xiao-Dong

doi:10.3892/etm.2017.4075

March-2017 Volume 13 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-2017 Volume 13 Issue 3

Full Size Image

Article Open Access

Effects of the modified electric convulsive treatment (MECT) on cell factors of schizophrenia

Authors:
- Yong‑Fang Guo
- Hua‑Bin Fu
- Zhi‑Yuan Liu
- Wei Lu
- Ke‑Yong Luo
- Hong‑Ri Zhu
- Wei‑Dong Ning
- Feng Chen
- Li-Yu Yang
- Xiao-Dong Zhou
View Affiliations / Copyright

Affiliations: 256th Clinical Department of Bethune International Peace Hospital of PLA, Zhengding, Hebei 050800, P.R. China

Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 873-876
|
Published online on: January 20, 2017

https://doi.org/10.3892/etm.2017.4075
Expand metrics +

Abstract

The expression of cell factors of schizophrenia and the effect of the modified electric convulsive treatment (MECT) were studied. In total, 156 patients with schizophrenia were selected, and divided into the drug group (70 cases) and the drug combined with MECT group (combined group) (86 cases) according to the treatment methods. In addition, 70 cases of healthy volunteers (control group) were selected according to the closest matching method based on 1:1 of age and gender. The drug treatment, consisted of anti‑psychotic drugs, such as risperidone 2‑8, quetiapine 300‑750, ziprasidone 80‑160 or aripiprazole 10‑30 mg/day, and for the control group, we used the electric spasm therapeutic instrument, Thymatron®IV Systems up to 6 times, 3 times a week. The levels of interleukin (IL)‑10, IL‑4, IL‑6 and IL‑1 were detected before and after treatment by ELISA. The positive and negative symptom scale (PANSS) was used to evaluate the efficiency. Before the treatment, IL‑1 and IL‑6 levels of drug and combined groups were significantly higher than those of the control group (P<0.05), while IL‑4 and IL‑10 had no difference with the control group. There was no significant difference of each factor between the drug and combined groups. After treatment, IL‑1, IL‑6 and IL‑10 of the drug group did not change compared to the levels before treatment, but IL‑4 increased significantly; IL‑1 and IL‑10 of the combined group did not change, while IL‑4 and IL‑6 increased significantly; IL‑1, IL‑4 and IL‑6 of the drug and combined groups were significantly (P<0.05) higher than those in the control group, but not IL‑10. IL‑1, IL‑4 and IL‑6 levels of the combined group were significantly higher (P<0.05) than those of the drug group. After treatment, the PANSS scores of the two groups decreased and the combined group decreased more significantly (P<0.05). The reduction rate of the combined group was significantly higher (P<0.05) than that of the drug group. The total efficiency of the combined group was significantly higher than that of the drug group, and after comparing these levels, there was statistical significance (P<0.05). IL‑1, IL‑4, IL‑6 and IL‑10 levels of the drug and combined groups before treatment were not associated with PANSS scores and the variation of IL‑1, IL‑4, IL‑6 and IL‑10 of the drug and combined groups had no correlation with the reduction rate of the PANSS. The results showed that, cell factors of schizophrenia had an abnormal expression, and medication and MECT can affect the expression level. In addition, MECT can improve the effect in the treatment of schizophrenia, but had no obvious correlation with the change of cell factors.

View Figures

View References

1	Girgis RR, Kumar SS and Brown AS: The cytokine model of schizophrenia: emerging therapeutic strategies. Biol Psychiatry. 75:292–299. 2014. View Article : Google Scholar : PubMed/NCBI
2	Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO and Mortensen PB: Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry. 168:1303–1310. 2011. View Article : Google Scholar : PubMed/NCBI
3	Kronfol Z and Remick DG: Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 157:683–694. 2000. View Article : Google Scholar : PubMed/NCBI
4	Rotter A, Biermann T, Stark C, Decker A, Demling J, Zimmermann R, Sperling W, Kornhuber J and Henkel A: Changes of cytokine profiles during electroconvulsive therapy in patients with major depression. J ECT. 29:162–169. 2013. View Article : Google Scholar : PubMed/NCBI
5	Sinha P, Sundar A Shyam, Thirthalli J, Gangadhar BN and Candade VS: Two decades of an indigenously developed brief-pulse electroconvulsive therapy device: a review of research work from National Institute of Mental Health and Neurosciences. Indian J Psychiatry. 58:31–37. 2016. View Article : Google Scholar : PubMed/NCBI
6	Flamarique I, Baeza I, de la Serna E, Pons A, Bernardo M and Castro-Fornieles J: Thinking about electroconvulsive therapy: the opinions of parents of adolescents with schizophrenia spectrum disorders. J Child Adolesc Psychopharmacol. Mar 16–2016.(Epub ahead of print). PubMed/NCBI
7	Benson-Martin JJ, Stein DJ, Baldwin DS and Domschke K: Genetic mechanisms of electroconvulsive therapy response in depression. Hum Psychopharmacol. 31:247–251. 2016. View Article : Google Scholar : PubMed/NCBI
8	Al-Asmari AK and Khan MW: Inflammation and schizophrenia: alterations in cytokine levels and perturbation in antioxidative defense systems. Hum Exp Toxicol. 33:115–122. 2014. View Article : Google Scholar : PubMed/NCBI
9	Gabay C, Lamacchia C and Palmer G: IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol. 6:232–241. 2010. View Article : Google Scholar : PubMed/NCBI
10	Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, Quraishi AA, Tawakkol N, D'Angelo R, Paulson AK, et al: Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2⁺ breast cancer by expanding the cancer stem cell population. Mol Cell. 47:570–584. 2012. View Article : Google Scholar : PubMed/NCBI
11	Cicuttini FM, Byron KA, Maher D, Wootton AM, Muirden KD and Hamilton JA: Serum IL-4, IL-10 and IL-6 levels in inflammatory arthritis. Rheumatol Int. 14:201–206. 1995. View Article : Google Scholar : PubMed/NCBI
12	Müller N and Schwarz MJ: Immune system and schizophrenia. Curr Immunol Rev. 6:213–220. 2010. View Article : Google Scholar : PubMed/NCBI
13	Kim Y-K, Myint A-M, Verkerk R, Scharpe S, Steinbusch H and Leonard B: Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients. Neuropsychobiology. 59:123–129. 2009. View Article : Google Scholar : PubMed/NCBI
14	Brown AS and Derkits EJ: Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry. 167:261–280. 2010. View Article : Google Scholar : PubMed/NCBI
15	Tyrka AR, Price LH, Kao H-T, Porton B, Marsella SA and Carpenter LL: Childhood maltreatment and telomere shortening: preliminary support for an effect of early stress on cellular aging. Biol Psychiatry. 67:531–534. 2010. View Article : Google Scholar : PubMed/NCBI
16	Potvin S, Stip E, Sepehry AA, Gendron A, Bah R and Kouassi E: Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 63:801–808. 2008. View Article : Google Scholar : PubMed/NCBI
17	Miller BJ, Buckley P, Seabolt W, Mellor A and Kirkpatrick B: Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 70:663–671. 2011. View Article : Google Scholar : PubMed/NCBI
18	Debnath M, Doyle K, Langan C, McDonald C, Leonard B and Cannon D: Recent advances in psychoneuroimmunology: inflammation in psychiatric disorders. Transl Neurosci. 2:121–137. 2011. View Article : Google Scholar
19	Xu M and He L: Convergent evidence shows a positive association of interleukin-1 gene complex locus with susceptibility to schizophrenia in the Caucasian population. Schizophr Res. 120:131–142. 2010. View Article : Google Scholar : PubMed/NCBI
20	Leonard BE, Schwarz M and Myint AM: The metabolic syndrome in schizophrenia: is inflammation a contributing cause? J Psychopharmacol. 26:33–41. 2012. View Article : Google Scholar : PubMed/NCBI
21	Zalcman S, Murray L, Dyck DG, Greenberg AH and Nance DM: Interleukin-2 and −6 induce behavioral-activating effects in mice. Brain Res. 811:111–121. 1998. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Effects of the modified electric convulsive treatment (MECT) on cell factors of schizophrenia

This article is mentioned in:

Abstract

Related Articles